Protecting Ovaries During Chemotherapy Through Gonad Suppression

Obstetrics and Gynecology

Volumn 126, Issue 1, 2015, Pages 187-195

  Elgindy, Eman ^a   Sibai, Hoda ^a   Abdelghani, Amany ^a   Mostafa, Magdy ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADORELIN DERIVATIVE; ANTINEOPLASTIC AGENT; GONADORELIN; PROTECTIVE AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA; META ANALYSIS; OUTCOME ASSESSMENT; OVARIAN PROTECTION; OVARIAN RESERVE; OVARY CANCER; OVARY FUNCTION; PARTHENOGENESIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; FERTILITY PRESERVATION; PREGNANCY RATE; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN RESERVE; PREGNANCY; PREGNANCY RATE; PRIMARY OVARIAN INSUFFICIENCY; PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 84932117939     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000905     Document Type: Review

References (58)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70.
3. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-62.
4. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31.
5. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog co-treatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011;95:906-14. e1-4.
6. SS Kim, Lee JR, Jee BC, Suh CS, Kim SH, Ting A, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010;53:740-52.
7. Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993;21:333-9.
8. Sutcliffe SB. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. Facts and thoughts. JAMA 1979;242:1898-9.
9. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embryo, oocytes, or ovaries. Oncologist 2007;12:1044-54.
10. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64-73.
11. Oktay K, Briggs D, Gosden RG. Ontogeny of folliclestimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 1997;82: 3748-51.
12. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. The Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008018. DOI: 10. 1002/14651858. CD008018. pub2.
13. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5. 0. 1. London (UK): The Cochrane Collaboration; 2008.
14. Churchill R, Higgins J, Chandler J, Tovey D, Lasserson T. Methodological Expectations of Cochrane Intervention Reviews (MECIR). London (UK): The Cochrane Collaboration; 2012.
15. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med 2009;151: 264-9, W64.
16. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;18:343; d5928.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
22. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, et al. Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013;121:78-86.
23. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31:903-9.
24. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropinreleasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8.
25. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-76.
26. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-41.
27. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropinreleasing hormone agonists for prevention of chemotherapyinduced ovarian damage; prospective randomized study. Fertil Steril 2009;91:694-7.
28. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7.
29. Gilani MM, Hasanzadeh M, Ghaemmaghami F, Ramazanzadeh F. Ovarian preservation with gonadotropinreleasing hormone analog during chemotherapy. Asia Pac J Clin Oncol 2007;3:79-83.
30. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007; 12:141-7.
31. Waxman JH, Ahmed R, Smith D, Wrigley PFM, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-62.
32. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32.
33. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134-40. e1.
34. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009; 91:705-14.
35. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685-718.
36. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013;19:26-36.
37. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006;91:1723-8.
38. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-6.
39. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2009;27:2677-85.
40. Gründker C, Emons G. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 2003;1:65.
41. Park EJ, Shin JW, Seo YS, Kim DW, Hong SY, Park WI, et al. Gonadotropin-releasing hormone agonist induces apoptosis of human granulosa-luteal cells via caspase-8,-9 and-3, and poly-(ADP-ribose)-polymerase cleavage. Biosci Trends 2011;5: 120-8.
42. S Zhao, Saito H, Wang X, Saito T, Kaneko T, Hiroi M Effects of gonadotropin-releasing hormone agonist on the incidence of apoptosis in porcine and human granulosa cells. Gynecol Obstet Invest 2000;49:52-6.
43. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004;19:1294-9.
44. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 2005;83:1333-8.
45. Azem F, Samara N, Cohen T, Ben-Yosef D, Almog B, Lessing JB, et al. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease. J Assist Reprod Genet 2008;25:535-8.
46. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008;89:166-73.
47. Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 2008;23:863-8.
48. Castelo-Branco C, Nomdedeu B, Camus A, Mercadal S, Martínez de Osaba MJ, Balasch J. Use of gonadotropin releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007;87:702-5.
49. Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, et al. Fertility status among women treated for aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:623-7.
50. Dann EJ, Epelbaum R, Avivi I, Ben Shahar M, Haim N, Rowe JM, et al. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005;20:2247-9.
51. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7.
52. Pereyra Pacheco B, Méndez Ribas JM, Milone G, Fernández I, Kvicala R, Mila T, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7.
53. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmers SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-11.
54. Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-9.
55. Balkenende E, Dahhan T, van der Veen F, Goddijn M. Comment on GnRH analogue co-treatment with chemotherapy for preservation of ovarian function. Fertil Steril 2011;96:e155-6.
56. Wang C, Chen M, Fu F, Huang M. Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis. PLoS One 2013;8:e66360.
57. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and metaanalysis of randomized trials. Cancer Treat Rev 2014;40: 675-83.
58. Leonard RC, Adamson D, Anderson R, Ballinger R, Bertelli G, Coleman RE, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010;28:590.